[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-myelogenous-leukemia---chronic-phase\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-myelogenous-leukemia---chronic-phase":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,61,100,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100599940","a-real-world-chronic-myelogenous-leukemia-cml-patient-disease-registry-to-describe-patient-experience-and-clinical-outcomes-among-patients-with-cml-receiving-approved-first-or-second-line-tyrosine-kinase-inhibitor-tki-therapy-100599940",false,"NCT07091019","A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy","ASC4REAL-2","Inclusion Criteria:\n\n* 18 years or older at the time of Ph+-CML-CP diagnosis.\n* Receiving TKI treatment (asciminib, bosutinib, dasatinib, imatinib, or nilotinib) in routine medical care either as initial therapy or after 1 prior TKI therapy.\n* Receiving treatment at US and US territories (i.e., Puerto Rico) medical practice (e.g. community-based, office-based, hospital-based, academic).\n* Signed informed consent form (ICF) prior to participation in the study including agreement to be tokenized so that the patient's anonymized RWD (EMRs and\u002For claims data) can be accessed.\n\nExclusion Criteria:\n\n* Active participation in an interventional trial that may influence the management of their Ph+-CML-CP disease.\n* Currently being treated with a CML TKI in 3L or beyond.\n* Known presence of T315I mutation.\n* Currently in TFR phase and are not on active CML TKI therapy.\n* Previously received treatment with a prior stem cell transplant\n* Pregnant or nursing (lactating) female.","ALL","18 Years","100 Years",{"count":20,"type":21},1000,"ESTIMATED","5 Years","OBSERVATIONAL","This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and describing long-term treatment outcomes.",[26],"Chronic Myelogenous Leukemia - Chronic Phase",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47],"CML,","CMP-CP,","ASC4REAL,","ASC4REAL-2,","chronic phase,","BCR-ABL, MMR,","TKI,","Tyrosine Kinase Inhibitor,","molecular response,","adult,","registry,","PRO,","patient reported outcome,","QOL,","quality of life,","asciminib,","bosutinib,","imatinib,","nilotinib,","dasatinib","RECRUITING","2026-06-22",{"date":51,"type":52},"2026-06-25","ACTUAL",{"date":54,"type":52},"2025-12-17",{"date":56,"type":21},"2033-04-20",{"name":58,"class":59},"Novartis Pharmaceuticals","INDUSTRY",15,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100500332","mcw-alphabeta-t-cell-and-b-cell-depletion-with-targeted-atg-dosing-100500332","NCT05794880","MCW Alpha\u002FBeta T-Cell and B-Cell Depletion With Targeted ATG Dosing","Matched Unrelated Donor and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha\u002FBeta T-Cell and B-Cell Depletion for Patients With Hematologic Malignancies With Targeted ATG Dosing Pilot Study, IDE 13641","Inclusion Criteria:\n\n1. Patient age \\\u003C 25 years. Both genders and all races eligible.\n2. Disease eligibility\n\n   * Acute myeloid leukemia, primary or secondary - Disease status: MRD negative (flow MRD ≤ 0.1%)\n   * Myelodysplasia\n   * Acute lymphoblastic leukemia - Disease status: MRD negative\n   * Chronic myelogenous leukemia - Disease status: chronic phase, accelerated phase or blast crisis now in second chronic phase\n   * Mixed lineage or biphenotypic acute leukemia- Disease status: MRD negative\n   * Lymphoblastic lymphoma - Disease status: in remission\n   * Burkitt's lymphoma\u002Fleukemia - Disease status: in remission\n   * Lymphoma after relapse - Disease status: in remission\n   * Other malignant hematologic diseases in remission (to be approved by PI)\n3. Karnofsky Performance Status ≥ 60% for patients 16 years and older and Lansky Play Score ≥ 60 for patients under 16 years of age (Appendix 1)\n4. Evaluation of organ status as per MCW BMT SOP\n5. Infectious disease criteria: No active untreated infection. Patients with possible fungal infections must have had at least 2 weeks of appropriate anti-fungal antibiotics and be asymptomatic.\n6. Signed consent by parent\u002Fguardian or able to give consent if ≥18 years.\n7. Negative pregnancy test for patients capable of childbearing potential\n8. Sexually active patients capable of child-bearing potential must agree to use adequate contraception (diaphragm, birth control pills, injections, intrauterine device \\[IUD\\], surgical sterilization, subcutaneous implants, or abstinence, etc.) for the duration of treatment. Sexually active men must agree to use barrier contraceptive for the duration of treatment.\n\nDonor Eligibility:\n\n1. Unrelated donor meets National Marrow Donor Program criteria for donation\n2. Infectious disease testing\n3. MCW BMT procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases.\n4. Only Peripheral blood stem cells will be used for stem cell source on this study therefore donor must be willing to undergo G-CSF mobilization and stem cell apheresis. Donor matching. High resolution typing at all loci to be performed.\n5. Unrelated Donor:\n\n   a. HLA typing of at least 10 alleles is required. Donor must be matched at 9\u002F10 or 10\u002F10 alleles (HLA A, B, C, DRB1, DQB1).Donor and collection center willing to undergo mobilization and apheresis\n6. Haploidentical Related Donor:\n\n   1. Haploidentical parent or other related donor: Minimum match level full haploidentical (at least 5\u002F10; HLA A, B, C, DRB1, DQB1 alleles), but use of haploidentical donors with extra matches (e.g. 6, 7, or 8\u002F10) encouraged.\n\nExclusion Criteria:\n\n1. Patients who do not meet disease, organ, or infectious criteria.\n2. No suitable donor\n3. Pregnant or lactating patients are ineligible as many of the medications used in this protocol could be harmful to unborn children and infants\n4. Receiving concomitant chemotherapy, radiation therapy; immunotherapy or other anti-cancer therapy for treatment of disease other than is specified in the protocol. Maintenance or other post-HCT therapy can be considered after discussion with the study PI.\n5. Participating in a concomitant Phase 1 or 2 study involving treatment of disease\n6. Active malignancy other than eligible disease specified in the protocol. Patients with prior malignancy can be eligible as long as at least 1 year post treatment for that malignancy.","0 Years","25 Years",{"count":71,"type":21},40,"INTERVENTIONAL",[74],"NA","This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha\u002Fbeta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival",[77,78,79,80,26,81,82,83,84,85,86,87,88],"Leukemia","Acute Myeloid Leukemia in Remission","Myelodysplasia","Acute Lymphoblastic Leukemia in Remission","Chronic Myelogenous Leukemia, Accelerated Phase","Chronic Myelogenous Leukemia With Crisis of Blast Cells","Biphenotypic Acute Leukemia","Lymphoblastic Lymphoma","Burkitt Lymphoma","Burkitt Leukemia","Lymphoma After Relapse","Other Malignant Hematologic Diseases in Remission","2026-05-08",{"date":91,"type":52},"2026-05-13",{"date":93,"type":52},"2023-05-01",{"date":95,"type":21},"2032-05",{"name":97,"class":98},"Medical College of Wisconsin","OTHER",1,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":72,"phases":109,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100630598","phase-3-tgrx-678-chinese-phase-iii-in-chronic-myelogenous-leukemia-cml-patients-100630598","NCT07489755","TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients","A Randomized, Open-label, Multi-center Phase III Study Evaluating Efficacy and Safety of TGRX-678 Comparing to Investigator Selected Tyrosine Kinase Inhibitor (TKI) in CML-CP Patients Resistant From or Intolerant to at Least 3 TKI Treatments","Inclusion Criteria:\n\n* Willing to consent and to follow study procedures\n* 18 years of age or above at time of screening; both sexes eligible\n* Diagnosed with CML-CP and was intolerant to or failed from at least 3 TKI treatments\n* ECOG score \\>= 2\n* Adequate hematological indicators and have not used blood products or Colony-Stimulating Factor (CSF)\n* Adequate kidney, liver and coagulation function\n* Adequate QTc interval as confirmed by electrocardiogram (ECG) test\n* Negative pregnancy result at screening for female patients of child-bearing potential\n* Willing to take contraceptive measure during the study (For male and female patients of child-bearing potential)\n\nExclusion Criteria:\n\n* Reception of TKI treatment or other anti-tumor treatments prior to first dose\n* History or presence of extramedullary leukemia\n* History of progression to CML-AP or BP\n* Presence or having uncontrolled condition for cardiovascular diseases\n* History of severe hemorrhagic disease\n* Presence of malabsorption or other conditions that may affect drug absorption\n* History of other primary malignancy within 5 years\n* Presence of continuous or active infection (including HIV, hepatitis B, hepatitis C)\n* In need for or having long-term immune suppressive treatment\n* Reception of major surgery 28 days before first dose\n* Presence of unrecovered toxicity due to anti-tumor treatment with CTCAE grade \\>=1\n* Presence of other conditions that the investigators or medical monitor deem unfit for the study",{"count":108,"type":21},180,[110],"PHASE3","A Phase III study evaluating the safety and efficacy of TGRX-678 in CML-CP patients resistant from or intolerant to at least 3 TKIs",[113,26],"Chronic Myelogenous Leukemia","NOT_YET_RECRUITING","2026-03-18",{"date":117,"type":52},"2026-03-24",{"date":119,"type":21},"2026-04-01",{"date":121,"type":21},"2031-05-01",{"name":123,"class":59},"Shenzhen TargetRx Co., Ltd.",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":72,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":99},"100522452","evaluation-of-advanced-practice-nurses-management-of-patients-with-chronic-myeloid-leukemia-100522452","NCT06082804","Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia","IPA-LMC","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* CML patient in chronic phase, eligible for oral therapy.\n* Newly diagnosed CML and\u002For initiating oral therapy :\n\n  * Patient changing treatment for non-response or loss of therapeutic response or toxicities, on the condition that these toxicities are resolved or grade I maximum at the time of inclusion.\n  * Newly start of oral therapy.\n* Patient eligible to a follow-up by an advanced practice nurse.\n* Patient capable to understand french and complete a questionnaire.\n\nExclusion Criteria:\n\n* Patient that had a follow-up \\> 3 months by an advanced practice nurse for CML before inclusion.\n* Patient changing treatment for toxicities, if these toxicities are still \\> grade I at inclusion.\n* Patient enrolled in another interventional research protocol for CML.\n* Pregnant women.\n* Patient under legal protection, deprived of liberty or unable to be included in a research protocol.",{"count":132,"type":21},60,[74],"Chronic Myeloid Leukemia (CML) affects 820 people per year in France (2018), half of them are older than 60 years old.\n\nTyrosine Kinase Inhibitors (TKI) are new kind of targeted therapy whose efficiency allow for a high rate of complete molecular response, leading to a disruption of treatment under certain conditions.\n\nOptimizing CML treatment is a major concern, particularly for adverse events management, treatment compliance and therapeutic response. Multiple studies demonstrated that grade ≤ II adverse events are most likely to be under reported by patients and clinicians. Although these adverse events are mostly reported by clinical examination, needing minimal treatment. These toxicities could alter daily and domestic living activities, potentially impacting treatment compliance and therapeutic response. Therefore, early detection of these adverse events is a major challenge for the prognosis and care of CML.\n\nThe Advanced Practice Nurse (APN), a new health care professional, acquired the skills needed to independently follow, manage and care the patients with medical approvals.\n\nAt international level, many studies, in oncology and in others domains, have been done to demonstrate the added value of the APN, particularly in improving patient's quality of life, management, care of drug-induced adverse events and treatment compliance.\n\nIn France, because of the recentness of the profession, only few studies were have been conducted. The goal of this study is to demonstrate the benefit of APN in clinical follow-up, quality of life, treatment compliance, and therapeutic response of CML patients. These effects could be managed thanks to early detection and management of ≤ grade II adverse events during consultation, in partnership with the patients, and in collaborative working.",[26],[137,138,139],"Advanced Practice Nursing","Quality of life","Adverse event","2026-03-02",{"date":142,"type":52},"2026-03-04",{"date":144,"type":52},"2023-11-29",{"date":146,"type":21},"2027-12",{"name":148,"class":98},"Centre Hospitalier Henri Duffaut - Avignon"]